Zanubrutinib is a selective next-generation covalent BTK inhibitor approved by the FDA for the treatment of adult patients with MCL who have received at least 1 prior therapy (9); it is under investigation for the treatment of patients with CLL (10, 11). This evidence concerns the gene BTK and mantle cell lymphoma.